Swiss National Bank Raises Stock Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Swiss National Bank lifted its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTXGet Rating) by 7.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,600 shares of the company’s stock after purchasing an additional 3,500 shares during the quarter. Swiss National Bank owned 0.18% of Karuna Therapeutics worth $6,654,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of KRTX. State Street Corp boosted its stake in Karuna Therapeutics by 22.3% in the first quarter. State Street Corp now owns 1,026,507 shares of the company’s stock worth $130,151,000 after buying an additional 187,142 shares in the last quarter. Lord Abbett & CO. LLC boosted its stake in Karuna Therapeutics by 52.9% in the first quarter. Lord Abbett & CO. LLC now owns 369,545 shares of the company’s stock worth $46,854,000 after buying an additional 127,840 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Karuna Therapeutics by 132.7% in the first quarter. Bank of New York Mellon Corp now owns 211,678 shares of the company’s stock worth $26,839,000 after buying an additional 120,709 shares in the last quarter. Viking Global Investors LP boosted its stake in Karuna Therapeutics by 12.8% in the first quarter. Viking Global Investors LP now owns 974,345 shares of the company’s stock worth $123,537,000 after buying an additional 110,681 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in Karuna Therapeutics by 51.8% in the first quarter. Jennison Associates LLC now owns 273,540 shares of the company’s stock worth $34,682,000 after buying an additional 93,290 shares in the last quarter.

Karuna Therapeutics Stock Up 3.0 %

Shares of Karuna Therapeutics stock opened at $231.85 on Wednesday. The company has a market cap of $7.97 billion, a PE ratio of -31.16 and a beta of 1.18. The business has a 50 day moving average of $221.89 and a 200 day moving average of $180.09. Karuna Therapeutics, Inc. has a 52 week low of $92.26 and a 52 week high of $278.25.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on KRTX. HC Wainwright upped their target price on Karuna Therapeutics from $160.00 to $320.00 and gave the stock a “buy” rating in a research note on Monday, August 15th. Loop Capital assumed coverage on Karuna Therapeutics in a research report on Tuesday, November 1st. They issued a “buy” rating and a $288.00 price objective for the company. Bank of America boosted their price objective on Karuna Therapeutics from $160.00 to $261.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Royal Bank of Canada boosted their price objective on Karuna Therapeutics from $292.00 to $293.00 in a research report on Thursday, September 29th. Finally, Stifel Nicolaus boosted their price objective on Karuna Therapeutics from $260.00 to $295.00 and gave the company a “buy” rating in a research report on Tuesday, September 13th. Fourteen equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $259.47.

Insider Activity at Karuna Therapeutics

In related news, Director Laurie J. Olson sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 11th. The stock was sold at an average price of $205.63, for a total transaction of $205,630.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Karuna Therapeutics news, CFO Troy A. Ignelzi sold 16,500 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $225.85, for a total value of $3,726,525.00. Following the completion of the transaction, the chief financial officer now owns 9,970 shares in the company, valued at $2,251,724.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Laurie J. Olson sold 1,000 shares of the stock in a transaction on Tuesday, October 11th. The stock was sold at an average price of $205.63, for a total value of $205,630.00. The disclosure for this sale can be found here. Insiders sold a total of 62,100 shares of company stock worth $13,994,073 over the last quarter. 16.20% of the stock is owned by corporate insiders.

About Karuna Therapeutics

(Get Rating)

Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis.

Recommended Stories

Institutional Ownership by Quarter for Karuna Therapeutics (NASDAQ:KRTX)

Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.